Intelligence Feed event · Equity · 2026-08-27

    Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial

    Question

    Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial

    Direct answer

    Mesoblast reported fiscal 2026 revenue of US$120.3 million, marking a transition to commercial-stage biotechnology operations. Product sales were driven almost entirely by RYONCIL, which contributed US$115.2 million. In clinical development, Mesoblast confirmed the completion of patient treatment in its pivotal Phase 3 study of rexlemestrocel-L for chronic low back pain, setting up prospective readouts for its cellular therapy pipeline.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-27
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial”, revision 1, evidence through 2026-08-27. https://marketontology.com/market-events/2026-08-27/mesoblast-delivers-120-3m-fy26-revenue-and-concludes-phase-3-back-pain-trial-2df0d7

    EQUITY
    Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial
    Mesoblast reported fiscal 2026 revenue of US$120.3 million, marking a transition to commercial-stage biotechnology operations. Product sales were driven almost entirely by RYONCIL, which contributed US$115.2 million. In clinical development, Mesoblast confirmed the completion of patient treatment in its pivotal Phase 3 study of rexlemestrocel-L for chronic low back pain, setting up prospective readouts for its cellular therapy pipeline.
    MESO
    Impact
    67
    AUG 27
    SIG
    88%
    MESO
    Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial
    Mesoblast reported fiscal 2026 revenue of US$120.3 million, marking a transition to commercial-stage biotechnology operations. Product sales were driven almost entirely by RYONCIL, which contributed US$115.2 million. In clinical development, Mesoblast confirmed the completion of patient treatment in its pivotal Phase 3 study of rexlemestrocel-L for chronic low back pain, setting up prospective readouts for its cellular therapy pipeline.
    → Commercial adoption of RYONCIL generating $115.2 million in net product sales establishes base cash flow for MESO while Phase 3 back pain trial completion de-risks pipeline valuation.
    Impact
    Mesoblast reported fiscal 2026 revenue of US$120.3 million, marking a transition to commercial-stage biotechnology operations. Product sales were driven almost entirely by RYONCIL, which contributed US$115.2 million. In clinical development, Mesoblast confirmed the completion of patient treatment in its pivotal Phase 3 study of rexlemestrocel-L for chronic low back pain, setting up prospective readouts for its cellular therapy pipeline.
    Affected
    MESO
    Transmission
    Commercial adoption of RYONCIL generating $115.2 million in net product sales establishes base cash flow for MESO while Phase 3 back pain trial completion de-risks pipeline valuation.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    MESOcommercial cash flow expansion and clinical milestone completionUp1-4wReported $120.3M revenue with $115.2M from RYONCIL and completed Phase 3 treatment.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month